pivotal history, adjudicated Chuck. which company's morning. event the to the thanks our Metzger, System milestone presentation date. perhaps post clinical trial Health of the system at by through LINC you, of X-year principal XX. presented Dr. pivotal begin of any our demonstrated major rate CGuardians Chris for with presented is recap on procedure, trial just carotid the call stent everyone of rate Ohio May I'd carotid months X.XX% data Course joining Interventional such Thank Chief And events to XX this lead lowest of The a to an independently data Vascular the significant our at for like the in CGuard outcomes most investigator,
X.XX%, focus remains first an we last first presented a DSMI XXXX. implant-driven bar which as results patient-first and anticipated build our established high the on of new approval the year of of of in toward U.S. half outcomes in the results These XX-day work strategy October clinical for
it As excellent IDE mirror closely we've is studies X,XXX be results patient patients involving can also trial. to results that they in are, CGuard across note treatment we've these remarkable as important outcomes the that in showing peer-reviewed in real-world this published multiple of similarity as seen FDA achieved with over literature seen the
submit premarket data XXXX. CGuard foundation long-term PMA of With superior consistently in the allow this has carotid to a outcomes. are we a robust of or quarter, and if U.S. CGuard approval first in believe Prime date the standard beginning which, Which to execute track implant. the the application FDA short- half us in launch XX,XXX gold on this to demonstrated commercial catalyze would hand, more has potential sold the we to on to devices of as than patient CGuard approved,
private placement of which the of in weeks the in proceeds full the also $XXX.X for $XX.X were up to few milestone-based announced transformational pleased just of announce X pursuant triggered presentation ago, of The exercise May financings Series results gross the million company. to We H X-year to we million warrants, of a first these XXXX. raised
support of vision our regarded Soleu, our as Velan Board company institutional investors very for show and including continue Rosalind, are of We grateful highly their as members Marshall Directors. Nantahala, Wace, OrbiMed, our who well to to the
of additional million. achieve work bring $XX.X to tirelessly continue We and significant milestones, remaining an gross would which additional trigger to tranches X the proceeds in
clearance of are of an of back FDA and Carotid for for in CGuard next X sales first system, the the number stent the three, XXXX. in two, include of CGuard CGuard completion which year. half one, number milestones quarters we half Number garden of of anticipate These TCAR of of which Stent FDA Switch commercial approval, Prime the for we from include premarket kit receipt announcement our the PMA receipt Prime to the United targeting States,
Turning be launch. high-caliber now We of the and with the critical to Group commercial engaged to firms, are and is med pleased one on commercial an we roles world-class for update ongoing U.S. prepare of candidates process the to preparedness our for operations This onboarding accelerate leading Mullins several market search very teams. robust tech to build-out a activities. the business our
Florida establishing will the be have Southeast capacity also announced previously and and support. in production headquarters U.S. including We we training customer
Our world-class operations, team the programs. with CAS for execution support drive market and and will growing our sales in launching TCAR U.S. our Prime leadership sales both and CGuard
Our implant set best-performing and accessory including with is track Prime. enhancements, on and submit stent next-generation tool complete plan system, neuroprotection allow SwitchGuard TCAR the to and to in us CGuard study a offer our remains platform TCAR kit compatible CGuard will cleared
reminder, procedure. the is MPS prevent to and switch carotid the blood filter generated it the closed to returning traveling procedure the the in embolic from designed an a As minimize brain to a integrated TCAR patient stenting to during loss guard passing circuit during platform debris the blood through
enrollment for and clinical Both track CGuardians III CGuardians II previous submission and from remain guidance. on
and reimbursement and broadest our investment tides the and endovascular before, toward address procedural further TCAR and in the anticipating performing an product intended innovation base done Cash when standard was time of products first physician care. was a to carotid As we've shifted programs ongoing both said revascularization
of by both asymptomatic with the first shift change. toward October, year TCAR this of be CEA leader stent is which approach, expanded in patients the in to we include are we implant well beginning Last CAS positioned the and standard determination CGuard marked believe national what and coverage in risk we ignited very best-in-class to believe coverage CMS' final a a
randomization United endarterectomy Canada, plus IMM enrollment X,XXX and across like or update CAS Israel, sites the IMM Stenting X the I plus intensive carotid IMM evaluating on Transfemoral versus XXX now a subjects IMM trial. alone, while evaluating and would versus of provide clinical Spain X medical management, States, trial CREST also CREST alone. to brief ongoing in
despite milestone by we tremendous XX% CGuard XX only introduced are The XX its had of the a we X investigational composite to used and as in stroke vessel week, that collateral following X FDA the with in into device pleased complete CREST for any up these the the death stroke years. to primary target This have enrollment endpoint cases very enrollment within days process is complete, announced to late and time. the approved included thereafter randomization is now trials and being and at
opportunity congratulations Meschia and to Dr. Executive contributed and and with sites our along Dr. next-generation the Dr. stent platform. this entire CREST have We to carotid completing Lal, Brott, appreciate study X in extend tremendous our Committee CGuard with investigators the
Turning into now New entered a University at to Siddiqui, Institute feasibility that Jacobs at Neurosurgery our of Chairman pipeline early conduct and carotid Prime York Adnan of severe agreement we CGuard an study to occlusion. expansion Professor Vice with stenosis the Dr. and the Buffalo of We previously strategic initiatives. announced for State and of
acute tandem and thrombectomy In conjunction lesions. presenting with with ischemic and stroke patients
believe prevention proprietary As superior these designed will CGuard during stent in we demonstrate that mesh provide and MicroNet stenting this its a and of acute Prime is stroke the study using safety embolic procedures. feasibility reminder, carotid artery with our to
a component anticipate strong to our strategy. growth the this this commitment study neuro critical the quarter. and reflects will in community our of investment first long-term be that Our patient enrolled represents We
over of second Finally, representing and $X.XX significant meet was we production anticipated the a growth of announce total million, to quarter for devices CGuard X.X% pleased year market last a quarter revenue are to demand. including the quarter of growth
CGuard year. We sold the implants quarter, during nearly representing over growth X,XXX X% period same the last of
potential CGuard of in have it in markets U.S. translated U.S. the the for As we line context how these the is worth results difference of top U.S., noting our quarterly and approach in outside potential current the for revenue. our revenue would served approval
we system. of of the of $X,XXX pricing through XXX,XXX total approximately $XXX the versus in U.S. reimbursement smaller channel without through per partners, transfer distribution Outside market procedures a resulting lower for in price an U.S., XX,XXX average reimbursement and pressure in a TCAR sales price compete much cash
to these devices a standard in in carotid all foundation robust patients new incredible clinical enabled markets investment share over Despite double-digit markets the served along an evidence with our studies XX us for intervention limitations, X,XXX best-in-class establishing in results, has XX,XXX care most of over of these of sold to build with having date.
reported of $X,XXX $XX.X sold we the the line million volume in in FDA stents approval been worth on at sales XXXX to a to our mix half quarter. have business competitor for would X,XXX TCAR CAS As million comparison Further, how last quarter, quarterly the a a perspective, procedures unit nearly assuming current TCAR equal would of put in U.S., top of $XX.X we revenue On an only that possible revenues approximately current revenue. with these ASPs. have in and translate it's the X,XXX first approach
of they U.S. our the So that did even market. of patients having without have terms treated the treated, device number patients nearly our half in entered would device
So the revenue up NPS for introduction sets of SwitchGuard market very into we with us favorably our believe U.S. growth that next significant our year. beginning entry along future the
point, world. review and team in the are carotid the We commercial enter financials. the Craig? over opportunity building demand, to Craig about know to turn to service are the world-class create thrilled how biggest the a and market to call this I'll At
